stoxline Quote Chart Rank Option Currency Glossary
  
Soleno Therapeutics, Inc. (SLNO)
79.79  0.41 (0.52%)    06-20 13:19
Open: 79.74
High: 80.23
Volume: 189,316
  
Pre. Close: 79.38
Low: 78.84
Market Cap: 4,021(M)
Technical analysis
2025-06-20 12:50:37 PM
Short term     
Mid term     
Targets 6-month :  95.25 1-year :  111.25
Resists First :  81.55 Second :  95.25
Pivot price 77.66
Supports First :  75.68 Second :  72.05
MAs MA(5) :  78.76 MA(20) :  77.16
MA(100) :  63.19 MA(250) :  54.72
MACD MACD :  1.5 Signal :  1.5
%K %D K(14,3) :  69.8 D(3) :  66
RSI RSI(14): 59.8
52-week High :  81.55 Low :  36.93
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SLNO ] has closed below upper band by 25.3%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 79.66 - 80.14 80.14 - 80.6
Low: 75.79 - 76.35 76.35 - 76.89
Close: 78.51 - 79.35 79.35 - 80.15
Company Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Headline News

Fri, 20 Jun 2025
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects - Insider Monkey

Fri, 20 Jun 2025
New Clinical Data Shows Promising Results for Prader-Willi Syndrome Treatment at Major Conference - Stock Titan

Wed, 21 May 2025
Rare Disease Leader Soleno Therapeutics Secures Speaking Slots at Major Healthcare Conferences - Stock Titan

Tue, 13 May 2025
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - Stock Titan

Sun, 11 May 2025
Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? - Yahoo Finance

Wed, 07 May 2025
Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 50 (M)
Shares Float 38 (M)
Held by Insiders 1.8 (%)
Held by Institutions 112.2 (%)
Shares Short 4,150 (K)
Shares Short P.Month 5,010 (K)
Stock Financials
EPS -4.74
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.78
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -52.5 %
Return on Equity (ttm) -105.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.02
Qtrly Earnings Growth 0 %
Operating Cash Flow -89 (M)
Levered Free Cash Flow -34 (M)
Stock Valuations
PE Ratio -16.79
PEG Ratio 0
Price to Book value 16.61
Price to Sales 0
Price to Cash Flow -44.89
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android